Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX with Bevacizumab or Panitumumab in Resectable Liver Metastases
NCT01508000Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2013
- Primary completion
- Sep 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of bevacizumab, panitumumab in colorectal cancer (CRC), sponsored by European Organisation for Research and Treatment of Cancer. Started Jun 2013; status: terminated.
02
Drugs
bevacizumabpanitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01508000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01508000.